% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Klostermann:302806,
      author       = {A. Klostermann and T. Debertshäuser and M. Benary and N.
                      Biernath and B. Erber and R. Tahbaz and M. Möbs and M.
                      Joosten and W. D. Schmitt and T. Kim and I. Jelas and L.
                      Chai and Y. Jegodka and U. Keller and D. Beule and S.
                      Ochsenreither$^*$ and M. De Santis and T. Schlomm and U.
                      Keilholz$^*$ and M. Knödler and D. Rieke$^*$},
      title        = {{I}mplementation and outcome of personalized treatment
                      strategies in advanced genitourinary cancers.},
      journal      = {ESMO open},
      volume       = {10},
      number       = {7},
      issn         = {2059-7029},
      address      = {[London]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-01346},
      pages        = {105497},
      year         = {2025},
      abstract     = {Outcome is dismal in patients with advanced genitourinary
                      (GU) cancers refractory to standard treatments. Molecular
                      analyses and subsequent discussion of cases in specialized
                      molecular tumor boards (MTBs) are increasingly incorporated
                      into clinical management to facilitate personalized
                      treatment. Data on this approach are lacking for GU
                      malignancies.We conducted a retrospective analysis of
                      patients with GU cancers discussed in the MTB at the
                      Charité between 2016 and 2023. Ethics approval was obtained
                      for prospective follow-up of patients after written informed
                      consent and for retrospective data analysis. Clinical
                      benefit was defined as complete response (CR), partial
                      response (PR) or stable disease (SD) >6 months or a
                      progression-free survival (PFS) ratio between molecularly
                      matched therapy (MMT) and previous non-MMT >1.3. Outcome was
                      assessed by the investigators.Among 126 identified MTB
                      patients, most patients had a rare tumor type (n = 59),
                      followed by adenocarcinoma of the prostate (n = 45),
                      urothelial carcinoma (n = 17) and clear-cell renal carcinoma
                      (n = 5). Molecular profiling included immunohistochemistry
                      (n = 80), panel sequencing (n = 110) and/or
                      whole-exome/-transcriptome sequencing (n = 21). Eleven
                      patients died before the final MTB discussion. At least one
                      treatment option for MMT was identified for 78/115 patients
                      $(68\%).$ Twenty-five patients were treated with an MMT
                      $(22\%),$ three of whom subsequently received a second MMT.
                      Eighteen MMTs were given in an off-label setting and two
                      within clinical trials. A clinical benefit was observed in
                      8/28 $(28.6\%)$ applied MMTs. A PFS-ratio >1.3 was achieved
                      in eight patients. Among patients with rare entities
                      discussed (n = 54), 42 patients had at least one MMT option
                      $(78\%),$ with 19 patients receiving at least one MMT
                      $(35\%).For$ a majority of GU cancer patients an MMT was
                      identified and responses were seen in heavily pretreated
                      patients. Additional controlled trials and integration of
                      comprehensive molecular analyses and subsequent personalized
                      therapy should be considered for patients with GU cancers,
                      especially those with rare histologies.},
      keywords     = {genitourinary cancer (Other) / molecular tumor board
                      (Other) / precision oncology (Other) / real-world data
                      (Other) / targeted therapy (Other)},
      cin          = {BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40602108},
      doi          = {10.1016/j.esmoop.2025.105497},
      url          = {https://inrepo02.dkfz.de/record/302806},
}